证券代码：300149 证券简称：睿智医药 公告编号：2025-64 睿智医药科技股份有限公司 关于为子公司与关联方开展融资租赁业务提供担保 暨关联交易的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 上述事项已经公司第六届董事会第十二次会议审议通过，独立董事专门会议 审议通过了上述议案，并授权公司管理层办理上述事项相关事宜。根据《深圳证 券交易所创业板股票上市规则》《公司章程》等相关法律法规的规定，上述事项 经公司董事会审议通过后，无需提交公司股东会审议。本次交易不构成《上市公 司重大资产重组管理办法》规定的重大资产重组，无须经过有关部门批准。 二、关联方基本情况 名称：上海美鑫融资租赁有限公司 统一社会信用代码：91310000MA1FL07T95 注册地址：中国（上海）自由贸易试验区富特西一路 477 号 4 层 B79 室 成立日期：2015 年 10 月 21 日 法定代表人：万冬琦 注册资本：20,000 万人民币 睿智医药科技股份有限公司（以下简称"公司"）于 2025 年 9 月 8 日召开的第 六届董事会第十二次会议审议通过了《关于为子公司与 ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-63 睿智医药科技股份有限公司 第六届董事会第十二次会议决议公告 为适度利用融资渠道，优化融资结构，满足经营发展需求，公司全资子公 司上海睿智医药研究集团有限公司（以下简称"上海睿智"）拟以售后回租方 式与上海美鑫融资租赁有限公司开展融资租赁业务，融资总金额为人民币298万 元，融资期限为36个月。公司拟为上述子公司开展融资租赁业务提供不可撤销 的连带责任保证担保。 上海睿智为公司全资子公司，虽未提供反担保，但公司对其具有绝对控制 权，且公司及子公司信誉及经营状况良好，财务风险可控，具备较好的偿债能 力。本次开展融资租赁业务不会给公司带来重大财务风险及损害公司利益，不 会对公司的正常经营和业务发展造成不良影响，不存在损害公司及全体股东， 特别是中小股东利益的情形。因此同意公司为子公司开展融资租赁业务提供担 保。 本议案已经公司董事会审计委员会和独立董事专门会议审议通过。具体 内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）上披露的相关公告。 本议案以6票同意，0票反对，0票弃权获得通过。 特此公告。 睿智医药科技股份有限公司 董 ...

Core Viewpoint - The announcement by Ruizhi Pharmaceutical Technology Co., Ltd. regarding the establishment of an industrial investment fund with a total subscription amount of 200 million RMB, primarily targeting the healthcare industry and focusing on innovative drugs [1][3]. Group 1: Fund Establishment Details - The fund will be established in partnership with Shenzhen Investment Holdings Donghai Investment Co., Ltd. and other limited partners, with a total subscription amount of 200 million RMB [1][3]. - The fund's name is Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industrial Partnership (Limited Partnership), with Ruizhi's subsidiary contributing 58 million RMB, accounting for 29% of the total subscription [3][5]. - The Luohu District-level mother fund will contribute 140 million RMB, representing 70% of the total subscription [3][4]. Group 2: Fund Management and Investment Focus - The fund will focus on equity investments in the healthcare industry, particularly in innovative drugs and medical devices [5][6]. - Shenzhen Investment Holdings Donghai will act as the general partner and fund manager, with a focus on industrial technology, digital intelligence, and life health sectors [5][6]. Group 3: Fund Terms and Conditions - The fund has a duration of 7 years, with a 4-year investment period followed by a 3-year exit period, and can be extended by 2 years with unanimous agreement [6]. - Management fees will be charged at 2% during the investment period and 1.5% during the exit period, with no fees during the extension period [6]. - Strict reinvestment requirements include relocating the headquarters of invested companies to Luohu or establishing subsidiaries there, ensuring that revenues remain in the district [6][7].

Group 1 - The actual controller and chairman of Yong'an Pharmaceutical, Chen Yong, has had his detention lifted, allowing him to resume his duties, which enhances investor confidence in the company's future development [1] - FTSE Russell announced the inclusion of BeiGene and WuXi AppTec in the FTSE China A50 Index, reflecting the increasing importance of A-share companies in the global capital market and foreign investment interest in China's innovative drug sector [2] - Otsuka Pharmaceutical's application for the targeted drug, Belimumab injection, for IgA nephropathy has been accepted, potentially filling a market gap in a field with limited treatment options and providing a new growth point for the company [3] Group 2 - Ruizhi Pharmaceutical announced a partnership to establish a fund focused on investing in innovative drugs and medical devices, which will enhance the company's resource reserves and align with current industry trends [4] - Menova's subsidiary has received approval for Mosapride Citrate Tablets in China, which is expected to generate new revenue growth for the company and strengthen its position in the pharmaceutical industry [5]

Group 1 - The company announced the establishment of a new partnership for investment in the pharmaceutical industry, involving its wholly-owned subsidiary Beihai Ruizhi Venture Capital Co., Ltd. [1] - The total committed capital for the new partnership, Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership (Limited Partnership), is set at 200 million yuan, with Beihai Ruizhi contributing 58 million yuan, representing 29% of the total commitment [1]

Group 1 - The core point of the article is that Ruizhi Pharmaceutical announced the approval of a proposal for joint investment with a professional investment institution by its wholly-owned subsidiary during the 11th meeting of the 6th board of directors [2] Group 2 - The announcement was made on the evening of September 3 [2] - The decision reflects the company's strategy to collaborate with professional investors to enhance its investment capabilities [2] - This move may indicate potential growth opportunities for the company in the pharmaceutical sector [2]

Core Viewpoint - The company, through its wholly-owned subsidiary Beihai Ruizhi, has entered into a partnership to establish a new investment fund focused on the healthcare industry, particularly innovative drugs and medical devices, with a total committed capital of 200 million yuan [1] Group 1: Investment Details - The partnership involves Beihai Ruizhi contributing 58 million yuan, representing 29% of the total committed capital [1] - The fund aims to invest primarily in innovative drugs, leveraging the expertise and capital advantages of professional investment institutions [1] Group 2: Strategic Implications - The investment is expected to enhance the company's capital operation capabilities and strengthen its competitiveness in the innovative drug sector [1] - The collaboration with professional investment institutions is anticipated to improve risk control and generate investment returns for the company [1]

Core Viewpoint - The company, Ruizhi Pharmaceutical, is establishing a partnership to invest in the healthcare industry, focusing on innovative drugs and medical devices, which is expected to enhance its capital operation capabilities and competitiveness [1] Investment Partnership - Ruizhi Pharmaceutical's wholly-owned subsidiary, Beihai Ruizhi Venture Capital Co., Ltd., signed a partnership agreement with Shenzhen Investment Control Donghai Investment Co., Ltd. and other limited partners to establish a new investment fund [1] - The total committed capital for the partnership is 200 million yuan, with Beihai Ruizhi contributing 58 million yuan, representing 29% of the total [1] Focus on Healthcare Sector - The newly formed partnership will primarily invest in the healthcare sector, with a strong emphasis on innovative drugs [1] - The collaboration with professional investment institutions is expected to leverage their investment capabilities, funding advantages, and risk control abilities to enhance the company's operations in the innovative drug industry [1]

Group 1 - The core point of the article is that Ruizhi Pharmaceutical (300149.SZ) has signed a partnership agreement to establish a new investment fund focused on the healthcare industry, particularly innovative drugs and medical devices [1] - The total committed capital for the partnership is RMB 200 million, with Beihai Ruizhi contributing RMB 58 million, representing 29% of the total [1] - The partnership involves collaboration with Shenzhen Investment Control Donghai Investment Co., Ltd. and other limited partners, indicating a strategic move to enhance investment capabilities in the healthcare sector [1] Group 2 - The newly established fund, tentatively named Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership (Limited Partnership), aims to invest primarily in innovative drugs [1] - The involvement of professional investment institutions suggests a structured approach to capital allocation in the healthcare market [1] - This initiative reflects a growing trend in the pharmaceutical industry towards investment in innovation and technology-driven healthcare solutions [1]

第六届董事会第十一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）第六届董事会第十一次会 议于 2025 年 9 月 3 日以通讯方式召开。会议通知以书面、电话或电子邮件方 式送达。会议应到董事 6 人，实到 6 人。会议由公司董事长WOO SWEE LIAN 先生主持，公司高级管理人员列席了会议。本次会议召集与召开符合有关法律、 行政法规、部门规章和《公司章程》的有关规定。经与会董事认真审议，形成 决议如下： 1、审议通过了《关于全资子公司与专业投资机构共同投资的议案》 同意公司全资子公司北海睿智创业投资有限公司（以下简称"北海睿智"） 与专业投资机构深圳市投控东海投资有限公司及其他有限合伙人深圳市罗湖产 业促进合伙企业（有限合伙）共同出资设立深圳市罗湖东海睿智医药产业合伙 企业（有限合伙）（暂定名，具体以企业登记机关最终核准登记的名称为准）， 全体合伙人认缴出资总额为人民币20,000万元，其中北海睿智作为有限合伙人 以自有资金出资人民币5,800万元，占认缴出资总额的29%。 证券代码：300149 ...